搜索
Ascendis Pharma A/S
ASND添加自选
243.910USD
-7.160-2.85%
收盘 07-31 16:00（美东）报价延迟15分钟
15.12B总市值
35.15市盈率 TTM
关于 Ascendis Pharma A/S 公司
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S简介
公司代码ASND
公司名称Ascendis Pharma A/S
上市日期Jan 28, 2015
CEOMoller Mikkelsen (Jan)
员工数量- -
证券类型Depository Receipt
年结日Jan 28
公司地址Tuborg Boulevard 12
城市HELLERUP
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Denmark
邮编2900
电话4570222244
网址https://ascendispharma.dk/
公司代码ASND
上市日期Jan 28, 2015
CEOMoller Mikkelsen (Jan)
Ascendis Pharma A/S公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
Ms. Lotte Soenderbjerg
Ms. Lotte Soenderbjerg
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
--
--
Dr. Kennett Sprogoee, Ph.D.
Dr. Kennett Sprogoee, Ph.D.
Executive Vice President, Head of Innovation and Research
Executive Vice President, Head of Innovation and Research
--
--
Mr. Scott T. Smith
Mr. Scott T. Smith
Chief Financial Officer, Executive Vice President, Member of the Executive Board
Chief Financial Officer, Executive Vice President, Member of the Executive Board
--
--
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
常见问题
Ascendis Pharma A/S的前五大股东是谁？
Ascendis Pharma A/S 的前五大股东如下：Mr. Flemming Steen Jensen
有多少机构持有Ascendis Pharma A/S(ASND)的股份？
截至2026Q1，共有582家机构持有Ascendis Pharma A/S的股份，合计持有的股份价值约为69.20M，占公司总股份的111.42%。与2025Q4相比，机构持股有所增加，增幅为-1676383.00。
哪个业务部门对Ascendis Pharma A/S的收入贡献最大？
在2026Q1，Commercial sale of products业务部门对Ascendis Pharma A/S的收入贡献最大，创收683.57M，占总收入的94.92%。